Dynavax Technologies Presents Positive Responses in Study of SD-101 With Keytrudaa

Dynavax Technologies Presents Positive Responses in Study of SD-101 With Keytrudaa

Dynavax Technologies (DVAX) said it presented findings in patients with metastatic melanoma in the dose escalation phase of an ongoing Phase 1b/2 study investigating SD-101, Dynavax’s intratumoral TLR9 agonist, in combination with KEYTRUDAA, an anti-PD-1 therapy developed by Merck (MRK), known as MSD outside the United States and Canada. The data showed a 100% overall response rate, with a complete response (CR) rate of 29%, which it said is a […]

Read More ˃